Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against NuVasive, Inc.

Rigrodsky & Long, P.A.:
  • Do you, or did you, own shares of NuVasive, Inc. (NASDAQ GS: NUVA )?
  • Did you purchase your shares before October 22, 2008, or between October 22, 2008 and July 30, 2013, inclusive?
  • Did you lose money in your investment in NuVasive, Inc.?
  • Do you want to discuss your rights?

Rigrodsky & Long, P.A., including former Special Assistant United States Attorney, Timothy J. MacFall, announces that a complaint has been filed in the United States District Court for the Southern District of California on behalf of all persons or entities that purchased the common stock of NuVasive, Inc. (“NuVasive” or the “Company”) (NASDAQ GS: NUVA) between October 22, 2008 and July 30, 2013, inclusive (the “Class Period”), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the “Complaint”).

If you purchased shares of NuVasive during the Class Period, or purchased shares prior to the Class Period and still hold NuVasive, and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 825 East Gate Boulevard, Suite 300, Garden City, NY at (888) 969-4242, by e-mail to info@rl-legal.com, or at: http://www.rigrodskylong.com/investigations/nuvasive-inc-nuva.

NuVasive is a medical device company focused on developing minimally disruptive surgical products and procedurally integrated solutions for the spine. The Complaint alleges that throughout the Class Period, defendants made materially false and misleading statements, and omitted materially adverse facts, about the Company’s business, operations and prospects. Specifically, the Complaint alleges that the defendants concealed from the investing public that: (1) the Company improperly submitted false claims to Medicare and Medicaid in violation of federal and state laws and regulations; and (2) as a result of the foregoing, the Company’s statements were materially false and misleading at all relevant times. As a result of defendants’ false and misleading statements, the Company’s stock traded at artificially inflated prices during the Class Period.

If you liked this article you might like

Biotech Movers: Cesca Up Strong After Securing CAR-T Cell Patent

Masimo's Stock Is a Great Buy Right Now

NXPI, AAPL, C: Jim Cramer's Views

Cramer: Demand Lifts Defense, Aerospace, Cyber-Security, Regional Bank Stocks

NuVasive (NUVA) Stock Tumbles on Q3 Revenue Miss, Outlook